Search…

Kangzhe Pharmaceutical: New drug Desidustat tablets for renal anemia approved for marketing in China.

13/03/2026

Kangzhe Pharmaceutical announced that the application for the marketing approval of the new drug Desidustat tablets for renal anemia was approved by the China National Medical Products Administration on March 13, 2026. The product is an innovative oral hypoxia-inducible factor-prolyl hydroxylase inhibitor, suitable for the treatment of anemia in non-dialysis adult patients with chronic kidney disease.

Latest

6 m ago

The continuous and severe sharp rise in oil prices will have a devastating impact on the economies of Japan and the Eurozone, which heavily rely on oil imports.

6 m ago

Due to the Middle East conflict driving investors towards safe-haven assets, the US dollar is expected to rise for a second consecutive week.

7 m ago

Business income surplus: Net profit in 2025 was 655 million yuan, a year-on-year decrease of 22.12%.

7 m ago

Chris Turner, Head of Foreign Exchange Strategy at the Dutch International Group, supports Japan's intervention actions. He said, "Coordinated intervention with the Federal Reserve could be more sustainable, as it builds on the idea that Washington is preparing to address the recent strength of the US dollar."

8 m ago

Recently, JA Solar signed a 105.68MW high-efficient module supply agreement with a core distributor in Japan. These modules will be fully entering the Japanese residential and commercial distributed market.

See all latest